SLPI regulates the expression the expression of IL-6 and IL-10 in Lymphocytes

GUERRIERI, D; REITERI, M; MAFFIA, P; TATEOSIAN, NANCY; CHULUYAN, E

Cordoba, Argentina

Congreso; VII Congreso Latinoamericano de Inmunología.; 2005

Previous works in our laboratory have demonstrated that Secretory Leucocyte ProteaseInhibitor (SLPI) decreased the proliferation of human T cells. In this study, we analyzed theexpression of different cytokines produced by lymphocytes treated with rhSLPI. In order toevaluate the capacity of SLPI to modulate the pattern of expression of cytokines we use a BDTMCBA Human Th1/Th2 Cytokine Kit II. This kit allows us to measure simultaneously IL-2, IL-4, IL-6,IL-10, TNF and IFN by flow cytometry in the supernatant of lymphocytes stimulated with rhSLPI(4 mg/ml, 5 days, 37ºC). The presence of rhSLPI increase the expression of IL-6 (from0,065±0,01 to 3,4±0,7 ng/ml) and IL-10 (from 0,02±0,01 to 0,4±0,1 ng/ml) meanwhile nosignificant effect was observed on the others cytokines. We also observed that IL-2 (8ng/ml)reverted the increase produced by rhSLPI of IL-6 (1,4±0.7 ng/ml) and IL-10 (0,3±0,04 ng/ml).Furthermore, rhSLPI (4 mg/ml) decreased the expression of T-box expressed in T-cell (T-bet) inlymphocytes stimulated with IL-2 (8 ng/ml) during 4 days through a Western blot. T-bet expressionis implicated in generating Th1 type of immune response. These results suggest that SLPI canmodulate the expression of cytokines leading to Th2 cytokine pattern of expression.